USA flag logo/image

An Official Website of the United States Government

A drug releasing urinary catheter

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
66332
Program Year/Program:
2003 / SBIR
Agency Tracking Number:
DK057918
Solicitation Year:
N/A
Solicitation Topic Code:
N/A
Solicitation Number:
N/A
Small Business Information
WHALEN BIOMEDICAL, INC
11 MILLER ST SOMERVILLE, MA 02143-
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 2
Fiscal Year: 2003
Title: A drug releasing urinary catheter
Agency: HHS
Contract: 2R44DK057918-02
Award Amount: $750,000.00
 

Abstract:

DESCRIPTION (provided by applicant): Catheter-associated urinary tract infection (UTIc) is the most common nosocomial infection acquired in hospitals and nursing homes. The goal of this Phase II program is to continue the development and evaluation of a new, drug releasing urinary catheter fabricated from silicone rubber containing the antiseptic agent chlorhexidine gluconate (CHG). The CHG is confined in a polyethylene glycol matrix uniformly dispersed in the elastomer, and it is released in sustained fashion over periods up to 4 weeks. This catheter material has been shown to be effective in vitro against organisms commonly associated with UTI. The choice of CHG as the antiseptic agent is based on its broad spectrum of activity, comparatively low toxicity, and low incidence of the development of bacterial resistance. In Phase II, methods for fabricating the catheters will be refined, and the effectiveness of the catheter material to inhibit or kill bacteria as a function of usage time evaluated. Toxicity studies required to fulfill the requirements of ISO 10993-18, a standard for medical device materials, will be conducted; and the shelf life of the catheters will be determined. Finally, a double blind, randomized trial of drug releasing versus nondrug releasing catheters in a large animal model will be conducted to measure efficacy in lessening or preventing the development of UTIc or pylonephritis over a 28 day period.

Principal Investigator:

Robert L. Whalen
6178684433
robert@whalen.net

Business Contact:

Pamela Rosengard
6178684433
PAMELA@WHALEN.NET
Small Business Information at Submission:

WHALEN BIOMEDICAL, INC.
11 MILLER STREET SOMERVILLE, MA 02143

EIN/Tax ID: 042836765
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No